http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
-
Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
-
Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
-
Guardant Health (GH) to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools
-
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
-
Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients
-
Guardant Health (GH) and ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
-
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
-
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
-
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
-
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
-
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
-
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
-
Guardant Health (GH) Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
-
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
-
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer
-
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health Named to TIME’s List of the Best Inventions of 2024
-
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024
-
Guardant Health (GH) Appoints Roberto A. Mignone to its Board
-
Roberto A. Mignone Joins Guardant Health Board of Directors
-
Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
-
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
-
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
-
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
-
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
-
Guardant Health to Participate in Upcoming Investor Conferences
-
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
-
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
-
Guardant Health's (GH) FDA-approved Shield Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
-
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
-
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
-
Guardant Health's (GH) Shield Blood Test Approved by FDA as Primary Screening Option, Clearing Path for Medicare Reimbursement
-
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
-
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
-
Guardant Health (GH) Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360 Test
-
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
-
Guardant Health (GH) Appoints Manuel Hidalgo Medina to its Board
-
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
-
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
-
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical t
-
Guardant Health Named to TIME100 Most Influential Companies
-
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
-
Guardant Health (GH): FDA Advisory Committee Panel Strongly Recommends Approval of Shield Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

